A reservoir type transdermal patch for delivery of ketorolac, a potent analgesic agent was studied. The low permeability of skin is the rate-limiting step for delivery of most of the drugs. Studies were carried out to investigate the eŠect of permeation enhancers on the in vitro permeation of ketorolac across rat skin. The reservoir type transdermal patch was fabricated and the core wasˆlled with gel system of a non ionic polymer HPMC (hydroxypropyl methyl cellulose) formulated in PBS (phosphate buŠer saline) solution of pH of 5.4 along with isopropyl alcohol at 25％ w/w concentration. Various permeation enhancers' viz. dimethyl sulphoxide, d-limonene, eucalyptus oil and transcutol (diethylene glycol monoethyl ether) were incorporated into the gel system. Permeation enhancement of ketorolac with diŠerent enhancers followed the order eucalyptus oil＞ transcutol＞ DMSO＞ d-limonene. Cyclic terpene containing eucalyptus oil was found to be the most promising chemical permeation enhancer for transdermal delivery of ketorolac. The increase in concentration of eucalyptus oil further enhanced drug permeation with maximum ‰ux being achieved at 10％ w/w of 66.38 mg/cm 2 /h. Further enhancement of permeation rate of ketorolac across skin was attained by application of abrading gel containing crushed apricot seed onto the skin. There was 5.16 times enhancement and ‰ux of 93.10 mg/cm 2 /h was attained. A reservoir type transdermal patch for delivery of ketorolac thus appears to be feasible of delivering ketorolac across skin.
INTRODUCTION
Ketorolac ( ( ± ) -5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, 2-amino-2-( hydroxy methyl)-1,3-propanediol; Mol. wt. 376.4 g/mol) is a prostaglandin synthetase inhibitor, a nonsteroidal anti-in‰ammatory drug with potent analgesic and moderate anti-in‰ammatory activities. 1) Ketorolac has been studied clinically and its e‹cacy and safety as an analgesic in cancer and postoperative pain has been established. Administered as injectable and oral formulations, it has shown high analgesic potency almost equivalent to that of morphine. 2) Unlike narcotic analgesics, ketorolac does not alter gastric motility or adversely aŠect respiration, nor is it associated with addiction potential as in case of narcotic analgesics; therefore, ketorolac is a relatively more favorable therapeutic agent for the management of moderate to severe pain. 3) Thus developing an alternative dosage form that is easy to administer; is painless; non invasive; easy to comply and avoidsˆrst pass metabolism, is worthwhile. The transdermal route encompasses all the above advantages.
Despite these advantages, only a limited number of drugs can be administered percutaneously, due to low skin permeability of most drugs across the skin. The penetration through stratum corneum is the ratelimiting step for delivery of most of the drugs. To overcome this problem, vehicles, 4) penetration enhancers, 5) ultra sound 6) and electro-transport 7) facilitated transdermal systems have been attempted in the development of a transdermal delivery system of ketorolac. Prodrug approach has also been investigated for enhanced dermal delivery. 8, 9) However, the most widely used technique involves use of chemical penetration enhancers or solvents that modify the thermodynamic activity.
In the present study, we therefore investigate the eŠects of penetration enhancers on the in vitro permeation of ketorolac from hyrogel gel formulation across rat abdominal skin to examine the feasibility of developing a transdermal system.
EXPERIMENTAL

Materials
Ketorolac was obtained as a gift sam- Ketorolac gel system was prepared in PBS (phosphate buŠer saline) solution by dissolving ketorolac and adding HPMC (hydroxyl propyl methylcellulose) with continuous stirring so as to uniformly disperse the polymer. Permeation enhancers were mixed with the vehicle before adding the polymer. The gel was kept overnight at ambient temperature in a tightly closed container to allow uniform gelling (cold dispersion method).
Transdermal patches (reservoir type) of ketorolac were fabricated byˆlling ketorolac gel preparation (0.25 g per cm sq.) within a shallow compartment made of a hollow ring shaped device and drug impermeable backing membrane (laminated aluminum foil). A micro porous adhesive tape of a larger area was stuck onto the impermeable backing membrane to bring the transdermal patch in intimate contact with the skin. The device was closed by a release liner on the open side (Fig. 1) .
Preparation and Method of Application of Abrasive Gel
The abrasive gel was prepared by heating distilled water to 80°C and adding to it crushed apricot seed (5％ w/w) (Prunus armeniaca ). The size of crushed pieces ranged between 354 and 251 mm. The polymer HPMC (2％ w/w) was then added slowly and allowed to disperse uniformly (hot dispersion method). It was then cooled to form viscous gel into which was entrapped crushed apricot shell pieces.
One g of the gel was topically applied with the help of indexˆnger on the depilated site before application of formulation and was gently massaged onto the skin for a period of two minutes and pressure ranging between 30 50 g/cm 2 . The crushed apricot pieces were dusted oŠ with soft cloth.
In Vitro Skin Permeation Studies The abdominal skin of Sprague-Dawley rat was clamped between the donor and the receptor chamber with the stratum corneum surface facing the receptor compartment of modiˆed Keshary Chien diŠusion cell after removing the hair with a clipper. The eŠective diŠusion area of the cell was 2.0 cm 2 and had a receptor volume of 11 ml. The receptor chamber wasˆlled with freshly prepared PBS (phosphate buŠer saline) solution pH 7.4. The diŠusion bath was maintained at 37±1°C and the solution in the receptor chambers was stirred continuously with the help of magnetic bead. Ketorolac gel (0.5 g) was gently placed in the donor chamber and spread evenly on the rat abdominal skin. The donor compartment was covered with Paraˆlm Mto prevent evaporative loss. One ml of the solution in the acceptor chamber was removed for drug content determination and replaced immediately with an equal volume of fresh PBS solution pH 7.4. Drug concentration was determined UV spectrophotometrically.
Analysis of In Vitro Drug Release Study Samples
Samples withdrawn wereˆltered through What-mannˆlter paper No. 42 and diluted whenever necessary. The samples were analyzed spectrophotometrically at 324 nm. The concentration of drug was determined from the regression equation generated from the calibration curve, y＝0.0285x＋0.0012, R 2 ＝ 0.999.
EŠect of Permeation Enhancers
Ketorolac gel system consisted of 2％ w/w ketorolac and 2％ w/w HPMC (hydroxyl propyl methylcellulose) in PBS solution at pH of 5.4 along with IPA (isopropyl alcohol) at 25％ w/w and permeation enhancers. The gel system for the reservoir compartment of the transdermal patch was prepared by cold dispersion method. Various enhancers' viz. DMSO (dimethy sulfoxides), eucalyptus oil, d-limonene and transcutol (diethylene glycol monoethyl ether) were added at 5％ w/w concentration. The concentration of the screened enhancer was further optimized at 7.5 and 10％ w/w.
Skin Irritation Studies
Transdermal patch of ketorolac gel was applied onto the dorsal skin of Wistar rats (220 250 g) which was shaved 24 h prior to study. The site of application was occluded with gauze and covered with non-sensitizing adhesive microporous tape. After 24 h, the gel was removed and the score of erythema was determined by Drazie test 10) as follows: 0-no eryhtema; 1-very slight erythema (barely perceptible); 2-well-deˆned erythema; 3-moderate to severe eryhtema and 4-severe erythema (beet redness) to slight eschar formation (injuries in depth).
Carrageenan Induced Paw Edema The anti-in‰ammatory e‹cacy was evaluated by carrageenan induced paw in‰ammation in Wistar rat (approx. 220 250 g). The rats were assigned to treatment groups so that each group was weight balanced. Ketorolac was administered via oral (2 mg/kg) and transdermal route 1 h before carrageenan injection. The transdermal patch was securely adhered over the depilated dorsal abdominal skin (9 cm 2 ). The rats received intraplantar injection of 50 ml of 0.5％ w/v carrageenan suspension into the left hind paw subcutaneously by inserting the needle into the central part of the paw. The paw volume was measured and compared to with that found in animals treated with carrageenan alone. The right hind paw which served as control was treated with physiological saline solution without carrageenan. 11) The in‰ammatory response was determined by measuring the changes in paw volumes with a screw gauge (Mitutoyo, Kanagawa, Japan) at 0, 2, 4, 6, 8 and 10 h after the carrageenan injection.
The degree of paw swelling was calculated as:
where, Vt is the volume of the carrageenan-treated paw, V is that of the non-treated paw.
where, Sc is the swelling of the control paw, St is that of the test formulation treated paw. The AUC (area under the curve) was determined by trapezoidal method. Acetic Acid Induced Writhing EŠect Ketorolac was administered via oral (2 mg/kg) and transdermal route 1 h before administration of writhing agent. The transdermal patch was securely adhered over the depilated dorsal abdominal skin (9 cm 2 ). The rats received intra peritoneally (i.p.) acetic acid (20 mg/ kg, 2 ml/kg) in deionized water. The number of writhes (i.e., abdominal constriction followed by dorsi‰exion and extension) occurring during a 15 min period beginning and 15 min after acetic acid administration, was measured. The results are expressed as percentage inhibition in writhes.
Histological Studies Transdermal patch formulations were applied for 24 h on the dorsal surface of excised rat skin mounted on the diŠusion cell. The transdermal patch was removed and the skin was wiped oŠ with tissue paper, the skins wereˆxed in 10 ％ v/v formalin solution in saline for at least 72 h before further processing it. The skin was sectioned vertically and each section was dehydrated and embedded in para‹n wax. The subdivided tissues were stained with hematoxylin and eosin. The sections were observed under microscope and photographed at 40× magniˆcation. Untreated skin served as control.
Data Analysis
The in vitro skin ‰ux was determined from Fick's law of diŠusion considering the transport of drugs across the skin barrier as a process of passive diŠusion. J SS , the skin ‰ux (mg/cm 2 /h), was determined from the slope of the linear portion of the cumulative amount permeated per unit area versus time plot. The lag time (T lag , h) was determined by extrapolating the linear portion of the curve to the abscissa. Enhancement ratio (ER) was calculated from the following equation:
ER＝J ss of test gel/J ss of control gel
Statistical Analysis
The results were analyzed Vol. 129 (2009) by paired, two tailed Student's t-test using Statistica for Windows (Version 5.0) from StatSoft, Inc., USA. The results were evaluated at probability level of 0.05. The results are reported as mean±SD.
RESULTS AND DISCUSSION
EŠect of Permeation Enhancers
EŠect of various chemical permeation enhancers on the permeation of ketorolac from transdermal formulations across rat abdominal skin was investigated. The enhancers evaluated were DMSO, eucalyptus oil, dlimonene and transcutol. The eŠectiveness of the enhancer was determined by comparing the steady state ‰ux of ketorolac from chemical enhancer containing gel system and that of control gel system. In vitro permeation proˆle is presented in Fig. 2 and the permeation parameters obtained after data analysis are reported in Table 1 . Among the penetration enhancers evaluated the following order was observed; eucalyptus oil＞ transcutol ＞DMSO＞ d-limonene.
DMSO demonstrated a ‰ux of 27.97 mg/cm 2 /h and a T lag of 1.97 h. There was an enhancement of 1.55 times. Being a powerful solvent DMSO can mix isothermally with water, it can displace water from the lipid head groups creating gaps around these head groups. DMSO is also capable of displacing water bound to protein head groups. Moreover due to its solvent power, high levels of sulfoxide within the membrane can improve drug partitioning and thus increase the ‰ux. 12) Transcutol showed a ‰ux of 29.72 mg/cm 2 /h and T lag of 2.05 h with ER of 1.65. Recent studies have shown that transcutol signiˆcantly increases the percutaneous penetration of various active substances, particularly when used in combination with suitable cosolvents. 13 17) Transcutol demonstrated enhanced ‰ux in comparison to DMSO but failed to reduce the lag time. This probably could be due to enhanced accumulation of ketorolac in skin. This enhancer has also shown skin accumulation of topically applied compounds without an increase in transdermal permeation. 18) Essential oils like eucalyptus oil are reported to be eŠective penetration enhancers for 5-‰ouorouracil traversing in human skin in vivo with maximum enhancement ratio of 34-fold. 19) The principal terpene element within eucalyptus oil is 1, 8-cineole, a cyclic ethers, and proven enhancer 20) but its e‹cacy as an enhancer are mixed. Eucalyptus oil could not enhance the permeation of lipophilic drug like estradiol. Similar results were also reported for the permeation of indomethacin, a lipophilic molecule. The study revealed that oxygen containing terpenes (carvone, 1, 8-cineole) were ineŠective 21) whereas hydrocarbon terpenes, especially limonene, were eŠective towards lipophilic drugs. The results of permeation enhancement of ketorolac, a hydrophilic drug also support the above observations towards which oil containing oxygen containing terpenes were eŠective. The permeation of penetration enhancer itself from the formulation is essential in order to achieve enhanced permeation of drug. The enhancer being lipophilic is believed to readily permeate out of gel into the skin. Eucalyptus oil at 5％ produced a ‰ux of 32.47 mg/cm 2 /h, an enhancement of 1.80 and a T lag of 1.34 h. eucalyptus oil demonstrated maximum permeation rate shortest T lag . It was therefore appropriate to study the eŠect of eucalyptus oil concentration on permeation rate of ketorolac. Increasing the concentration of eucalyptus oil to 7.5％ and 10％ concentration produced a ‰ux of 54.79 and 66.38 mg/cm 2 /h, an enhancement of 3.04 and 3.68 times and reduction of T lag to 1.14 and 1.08 h respectively. Further increase in eucalyptus oil concentration was not justiˆed due to skin irritation potential of the oil on prolonged contact with the skin.
These essential oils probably modify the solvent nature of the stratum corneum, improving drug partitioning into the tissue. Terpenes are generally good solvents and permeate skin well, 22) with loss of terpenes, from a formulation there could be an alteration of the thermodynamic activity of the permeant. Terpenes may also modify drug diŠusivity through the membrane and bring about a reduction of the lag time for permeation, indicating increase in diŠusivity of the drug through the membrane following terpene treatment. X-ray diŠraction studies have also indicated that d-limonene and 1,8-cineole disrupt stratum corneum bilayer lipids. 23) EŠect of Pretreatment with Abrading Gel Attempts were made to enhance the permeation of ketorolac across skin by abrading the upper skin layer with the help of abrading gel made of crushed apricot seed. There was 5.16 times enhancement in permeation of ketorolac across rat skin from formulation containing ketorolac (2％ w/w), HPMC (2％ w/w), IPA (25％ w/w) and eucalyptus oil (10％ w/w) prepared in PBS solution of pH 5.4. The J ss and T lag of 93.10 mg/cm 2 /h and 1.09 h were attained respectively after pretreatment.
Skin Irritation Studies
The results of the skin irritation studies based on visual observation score suggest that the formulations were safe to be applied on skin. The scores for d-limonene and Transcutol were between 0 1; while that for eucalyptus oil and DMSO were between 0 2.
Histological Studies The control skin (Fig.  3A) showed intact stratum corneum with no swelling of epidermis. No in‰ammatory cells were seen. The normal skin stratiˆcation was intact. Various chemical enhancers dramatically aŠected the skin. Transdermal formulation containing d-limonene ‰uidized the inner lipid layers and mild increase in the number of in‰ammatory cells was observed but the stratum corneum was found to be almost intact (Fig. 3B) . Formulation containing DMSO demonstrated signiˆcant ‰uidization of the inner dermis; the stratum corneum was seen disrupted though in‰ammatory cells were not observed (Fig. 3C) . Transdermal formulation containing eucalyptus oil ‰uidized the inner dermal lipids; the skin was found swollen with slight increase in the number of in‰ammatory cells (Fig.  3D) . On treatment of skin with formulation containing transcutol it was observed that only the epidermal portion had swollen with slight ‰uidization in this part while the basic stratiˆcation of the skin was almost maintained (Fig. 3E) . The eŠect of abrading the skin with abrading gel followed by treatment with transdermal formulation containing eucalyptus oil was observed on the skin. Stratum corneum was disrupted the skin lipids were vastly ‰uidized and the skin appeared swollen (Fig. 3F) .
Anti-in‰ammatory Response
The formulation showed a prominent increase in activity in the carrageenan induced paw in‰ammation model. Fig. 4 represents the anti in‰ammatory activity after oral administration and after transdermal application after treatment with abrading gel.
Ketorolac transdermal patch formulation demonstrated comparable anti-in‰ammatory potential to orally administered ketorolac. The anti-in‰ammatory potential was measured in terms of the AUC of graph plotted between diŠerence in paw diameter and time. Compared to the ％ AUC for untreated paw which was taken as 100％, oral administration showed swell- ing of 64.04％ while transdermal application after pretreatment demonstrated swelling of 60.67％. Maximum percentage inhibition was observed at 6 h and 4 h for oral and transdermal application after pretreatment of 50％ and 45.45％ respectively. There is clear evidence of enhanced permeation with quicker onset of action for the transdermal formulation applied after pretreatment. Abrasion of skin by crushed seeds of apricot probably helps in removing if not completely at least partially the upper stratum corneum thus aiding permeation enhancement.
Antinociceptive Response There was 88.10％ inhibition in writhing on oral administration was observed while application of transdermal application without pretreatment and after pretreatment demonstrated 50％ and 85.71％ inhibition in writhing response (Fig. 5) . The acetic acid induced writhing response is a sensitive procedure to evaluate peripherally acting analgesics. The response is thought to be mediated by peritoneal mast cells, 24) acid sensing ion channels 25) and the prostaglandin pathways. 26) The reservoir type transdermal patch consisting of ketorolac gel thus appears promising in delivering the drug across skin.
